US2023293506A1PendingUtilityA1

Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones

81
Assignee: IO THERAPEUTICSPriority: Mar 10, 2016Filed: May 19, 2023Published: Sep 21, 2023
Est. expiryMar 10, 2036(~9.6 yrs left)· nominal 20-yr term from priority
Inventors:Roshantha A. ChandraratnaMartin E. Sanders
A61P 11/06A61P 37/08A61K 45/06A61K 31/192A61K 9/0019A61P 37/02A61K 9/0053A61K 9/0043A61K 31/4418A61K 31/198A61K 31/44A61P 19/02A61P 29/00A61P 19/06A61P 13/12A61P 17/00A61P 17/06A61P 21/00A61P 25/00A61P 11/00A61P 1/00A61P 9/14A61K 31/216A61P 37/00Y02A50/30A61K 2300/00
81
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present specification provides methods of treating a transplant rejection, pulmonary fibrosis, or glomerulonephritis with a combination of a RXR agonist and a thyroid hormone.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of treating a transplant rejection, the method comprising administering to an individual in need thereof a therapeutically effective amount of a RXR agonist and a thyroid hormone, wherein the RXR agonist has the structure of Formula II 
       
         
           
           
               
               
           
         
         wherein R is H or lower alkyl of 1 to 6 carbons; or a pharmaceutically acceptable salt thereof; 
         wherein administration of the RXR agonist and the thyroid hormone treats the transplant rejection in the individual more effectively than either the RXR agonist or the thyroid hormone alone. 
       
     
     
         2 . The method according to  claim 1 , wherein is the RXR agonist is a selective RXR agonist comprising 3,7-dimethyl-6(S), 7(S)-methano, 7-[1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphth-7-yl]2(E), 4(E) heptadienoic acid. 
     
     
         3 . The method according to  claim 1 , wherein the RXR agonist is 3,7-dimethyl-6(S), 7(S)-methano, 7-[1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphth-7-yl]2(E), 4(E) heptadienoic ethyl ester. 
     
     
         4 . The method according to  claim 1 , wherein the thyroid hormone is thyroxine. 
     
     
         5 . The method according to  claim 1 , wherein the therapeutically effective amount of an ester of the RXR agonist having the structure of Formula II is about 0.001 mg/day to about 1000 mg/day. 
     
     
         6 . The method according to  claim 1 , wherein the therapeutically effective amount of the RXR agonist is about 0.001 mg/day to about 1000 mg/day. 
     
     
         7 . The method according to  claim 1 , wherein the therapeutically effective amount of the RXR agonist is about 1 mg/day to about 100 mg/day. 
     
     
         8 . The method according to  claim 4 , wherein the therapeutically effective amount of the thyroxine is about 12.5 μg/day to about 250 μg/day. 
     
     
         9 . The method according to  claim 4 , wherein the RXR agonist and the thyroxine are both administered substantially simultaneously. 
     
     
         10 . The method according to  claim 4 , wherein the RXR agonist and the thyroxine are administered on different schedules. 
     
     
         11 . A method of treating pulmonary fibrosis or glomerulonephritis, the method comprising administering to an individual in need thereof a therapeutically effective amount of a RXR agonist and a thyroid hormone, wherein the RXR agonist has the structure of Formula II 
       
         
           
           
               
               
           
         
         wherein R is H or lower alkyl of 1 to 6 carbons; or a pharmaceutically acceptable salt thereof; 
         wherein administration of the RXR agonist and the thyroid hormone treats the pulmonary fibrosis or glomerulonephritis in the individual more effectively than either the RXR agonist or the thyroid hormone alone. 
       
     
     
         12 . The method according to  claim 11 , wherein is the RXR agonist is a selective RXR agonist comprising 3,7-dimethyl-6(S), 7(S)-methano, 7-[1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphth-7-yl]2(E), 4(E) heptadienoic acid. 
     
     
         13 . The method according to  claim 11 , wherein the RXR agonist is 3,7-dimethyl-6(S), 7(S)-methano, 7-[1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphth-7-yl]2(E), 4(E) heptadienoic ethyl ester . 
     
     
         14 . The method according to  claim 11 , wherein the thyroid hormone is thyroxine. 
     
     
         15 . The method according to  claim 11 , wherein the therapeutically effective amount of an ester of the RXR agonist having the structure of Formula II is about 0.001 mg/day to about 1000 mg/day. 
     
     
         16 . The method according to  claim 11 , wherein the therapeutically effective amount of the RXR agonist is about 0.001 mg/day to about 1000 mg/day. 
     
     
         17 . The method according to  claim 11 , wherein the therapeutically effective amount of the RXR agonist is about 1 mg/day to about 100 mg/day. 
     
     
         18 . The method according to  claim 11 , wherein the therapeutically effective amount of the thyroxine is about 12.5 μg/day to about 250 μg/day. 
     
     
         19 . The method according to  claim 14 , wherein the RXR agonist and the thyroxine are both administered substantially simultaneously. 
     
     
         20 . The method according to  claim 14 , wherein the RXR agonist and the thyroxine are administered on different schedules. 
     
     
         21 . The method according to  claim 11 , wherein the method treats pulmonary fibrosis. 
     
     
         22 . The method according to  claim 11 , wherein the method treats glomerulonephritis.

Join the waitlist — get patent alerts

Track US2023293506A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.